Yes Hoy, it seems that a lot of RNAi requires chemical help. Agreed, pharma may like the idea but their drugs would only be used for a very short time. Not much in that for them but what you say is definitely on the cards.
I am wondering what they can do to deviate much from TT. Different shrnas, same vector but something else new?? The IND could be an issue if we change it too much...... but if pharma are in, the IND gets a lot easier.
What about using a fourth or fifth shrna? The use of a fourth and fifth drug works well in many cases of HCV when relapse occurs.
A friend, who is cirrhotic and has the difficult to treat G3 HCV, recently relapsed after a six month course of Sof/Dac. She will be re-treated with an experimental, five or six pronged cocktail. (Before you ask Blane..... we are going to add Sofosbuvir to Vpak and then add Riba after one month.)
I'm sure that eventually they will find better and better combinations of shrnas that won't require chemical help.
- Forums
- ASX - By Stock
- BLT
- Panno speaks on recent changes
Panno speaks on recent changes, page-13
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online